Sarah A. Holstein, MD, PhD is an Associate Professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center. She is the Team Leader of the Myeloma/Plasma Cell Dyscrasia Group at the Fred and Pamela Buffett Cancer Center. She previously served as a myeloma specialist at the University of Iowa and the Roswell Park Cancer Institute. She is a physician-scientist whose basic science, translational and clinical research focuses on myeloma. Her laboratory program has been funded by sources such as the National Cancer Institute, the American Society of Hematology and the PhRMA Foundation and focuses on the development of novel therapeutic agents for myeloma with a particular interest in the development of agents that disrupt Rab GTPase function. Her clinical research has concentrated on the role of maintenance therapy following autologous stem cell transplant. She has served as a member of the NCCN Multiple Myeloma Panel and currently serves on multiple other myeloma committees, including the Alliance myeloma committee. She has published more than 70 peer-reviewed articles and as well as multiple book chapters. She will be joining the 2020 Editorial Leadership team of Clinical Pharmacology & Therapeutics as an Associate Editor.
A/Professor Holstein's attendance is supported by Celgene's sponsorship to Blood 2019.Back to speakers